Skip to content
Axcess News – Lifestyle
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
March 31, 2026
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 5, 2026
←
Previous Page
1
2